"Today's approval provides an additional treatment option for patients with cUTIs who have limited or no alternative treatment options," said John Farley, M.D., M.P.H., acting director of the Office of Infectious Diseases in the FDA's Center for Drug Evaluation and Research. "A key global challenge the FDA faces as a public health agency is addressing the threat of antimicrobial-resistant infections, like cUTIs. This approval represents another step forward in the FDA's overall efforts to ensure safe and effective antimicrobial drugs are available to patients for treating infections."
The safety and effectiveness of Fetroja was demonstrated in a study of 448 patients with cUTIs. Of the patients who were administered Fetroja, 72.6% had resolution of symptoms and eradication of the bacteria approximately seven days after completing treatment, compared with 54.6% in patients who received an alternative antibiotic. The clinical response rates were similar between the two treatment groups.
More on Marylandian
- The Global Technology & Business Services Council launches to globally collaborate, promote and represent the industry
- PINC Named 2020 Food Logistics' Top Green Provider
- COVID-19 Virtual Waiting Room Solution for Small Businesses Helps to Ensure Client Safety
- Author Pens "The Purse" Offering Advice on Avoiding Unhealthy Relationships
- GP Strategies Partners with Whisbi to Provide Innovative Digital Sales Capabilities to Automotive Dealerships
Labeling for Fetroja includes a warning regarding the higher all-cause mortality rate observed in Fetroja-treated patients compared to those treated with other antibiotics in a trial in critically ill patients with multidrug-resistant Gram-negative bacterial infections. The cause of the increase in mortality has not been established. Some of the deaths were a result of worsening or complications of infection, or underlying co-morbidities. The higher all-cause mortality rate was observed in patients treated for hospital-acquired/ventilator-associated pneumonia (i.e.nosocomial pneumonia), bloodstream infections, or sepsis. The safety and efficacy of Fetroja has not been established for the treatment of these types of infections.
The most common adverse reactions observed in patients treated with Fetroja included diarrhea, constipation, nausea, vomiting, elevations in liver tests, rash, infusion site reactions, candidiasis (yeast infection), cough, headache and hypokalemia (low potassium). Fetroja should not be used in individuals with a known history of severe hypersensitivity to beta-lactam antibacterial drugs.
Fetroja received the FDA's Qualified Infectious Disease Product (QIDP) designation. The QIDP designation is given to antibacterial and antifungal drug products intended to treat serious or life-threatening infections under the Generating Antibiotic Incentives Now (GAIN) title of the FDA Safety and Innovation Act. As part of QIDP designation, Fetroja was granted Priority Review under which the FDA's goal is to take action on an application within an expedited time frame.
More on Marylandian
- "Why they are not Dying" Centenarians and their Resilience in the Age of COVID-19
- Best Dedicated Servers in Europe Network and PoPs
- American BioDefense Institute Commends Congressman Gosar For BioSecurity Amendment
- 2nd Annual Mile High Denver Boutique Week!
- Evolve IP Releases RECAP – AI Driven Speech Analytics And Voice Recording Platform For Microsoft Teams, Unified Communications and Contact Center
The FDA granted the approval of Fetroja to Shionogi & Co., Ltd.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Media Inquiries: Kristen Pluchino, 240-402-0861, Kristen.Pluchino@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
SOURCE U.S. Food and Drug Administration
Filed Under: Business
Latest on Marylandian
- Makita Trusts Blades Direct & Bladesdirect.net as The Newest Distributor
- Protecting Remote Workers: Intellectmap Launches Remote Work Cybersecurity Solution
- Ocean Conservation Nonprofit, OctoNation, 1 of 14 in North America Accepted to Facebook Community Accelerator Program
- AI.Reverie Awarded $1.5M AFWERX Phase 2 SBIR Contract from U.S. Air Force
- First Published Clinical Trial Using Live Biotherapeutic Candidate In COVID-19 Patients Suggests Role In Improving Outcomes
- Acumentrics Announces New Website Launch
- Reinvent yourself in the Workplace Adjusting to COVID-19
- 4e Brands North America Issues Nationwide Voluntary Recall of Hand Sanitizer Due to Potential Presence of Undeclared Methanol (Wood Alcohol)
- Trump visit to Atlanta focuses on I-75 South expansion
- Meeting Notice: Maryland Young Farmers Advisory Board to Meet July 15 via Teleconference
- PreK-12 Instructional Resource Providers Adjust to a COVID-19-Defining Market
- Maryland's Best Ice Cream Trail Returns for 2020 Season
- New Partner at Itero Group Signals Continued Growth
- Emily Rucinski, CPA, CCIFP®, Joins The Hoffman Group, LLC
- Travel + Leisure Readers give San Miguel De Allende a reason to Celebrate as it ranks in World's Best Awards
- MULTI-FUN project aims to enable multi-materials metal additive manufacturing for complex 3D parts without size constraints
- Movilitas.Cloud™ Verification Router Service (VRS) Solution Simplifies DSCSA Compliance for Pharmaceutical Wholesale Distributors and Manufacturers
- Sage Intacct Names Alta Vista Technology a Premier Partner
- Axiros AXESS ACS Enables UK ISP, Origin Broadband, With TR-069 Device Management Solution
- Newest Analysis from ImmersivEdge Advisors Helps Investors Make the Right Moves in the Dynamic AR & Smartglasses Industry